A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
A phase 1/2 trial of MCLA-129 in triple-negative breast cancer, run by Shenzhen Majory Biotechnology Co., Ltd., now recruiting.
Overview
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) is a phase 1/2 interventional study registered as NCT07208149 by Shenzhen Majory Biotechnology Co., Ltd., with 42 participants planned, started 2026-01-29 and due to reach its primary completion in 2028-09-01. Interventions recorded: MR001 Bispecific Antibody for Injection.
Similar pages
not linked directly; found by shared links- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPersonalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialNuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialStudy of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Shares MCLA-129 and the tag pipeline.
- TrialDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.